https://www.oncologynurseadvisor.com Sat, 14 Oct 2023 02:52:51 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/myeloproliferative-neoplasms/pruritus-may-mark-severe-symptomology-myeloproliferative-neoplasms/ Mon, 24 Apr 2023 14:20:00 +0000 https://www.oncologynurseadvisor.com/?p=106814 Researchers assessed clinical incidence of pruritus in patients with myeloproliferative neoplasms.]]> https://www.oncologynurseadvisor.com/home/hot-topics/side-effect-management/steven-johnson-syndrome-toxic-epidermal-necrolysis-sjs-ten-graft-vs-host-disease/ Thu, 01 Dec 2022 15:40:00 +0000 https://www.dermatologyadvisor.com/?p=95845 Study authors assessed the clinicopathology, complications, and outcomes of patients with Steven-Johnson Syndrome (SJS)- and toxic epidermal necrolysis (TEN)-like acute graft-vs-host disease (aGVHD).]]> https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/american-society-of-clinical-oncology-asco/asco-2022/nurse-navigator-geriatric-toxicity-screening-referrals-treatment-risk/ Wed, 15 Jun 2022 15:00:00 +0000 https://www.oncologynurseadvisor.com/?p=100126 A pilot study delegated screening assessments to nurse navigators to determine if such a program would increase referrals to supportive services for older older patients.]]> https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/american-society-of-clinical-oncology-asco/asco-2022/adt-prostate-cancer-disease-transition-risk-factors-depression/ Tue, 14 Jun 2022 15:00:00 +0000 https://www.oncologynurseadvisor.com/?p=100102 A survey of men with prostate cancer sought to identify when these patients were most vulnerable to symptoms of depression and/or anxiety.]]> https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/american-society-of-clinical-oncology-asco/asco-2022/acute-leukemia-cd7-cart-therapy-induced-remission-treatment-risk/ Mon, 13 Jun 2022 16:00:00 +0000 https://www.oncologynurseadvisor.com/?p=100078 Preliminary results of a clinical trial investigating the efficacy of CAR-T therapy in pediatric patients with CD7+ ALL/lymphoma were presented at ASCO 2022.]]> https://www.oncologynurseadvisor.com/home/headlines/conference-coverage/american-society-of-clinical-oncology-asco/asco-2022/myeloproliferative-neoplasms-effect-gender-bias-surveys-patients-treatment/ Fri, 10 Jun 2022 15:00:00 +0000 https://www.oncologynurseadvisor.com/?p=100043 Gender balance in cancer surveys was found to have relatively little effect on survey outcomes, according to results of a study presented at the 2022 ASCO Annual Meeting. Surveying patients with myeloproliferative neoplasms (MPN) has given valuable insight into polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) subtypes. However, independent surveys have included a…]]> https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/leukemia-aml-tumor-lysis-syndrome-incidence-infection-initial-days-treatment-risk/ Wed, 25 May 2022 15:00:00 +0000 https://www.oncologynurseadvisor.com/?p=99269 A retrospective analysis sought to determine the real world outcomes for patients with AML treated with venetoclax and azacitidine or decitabine.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/lymphoma-dlbcl-cardio-toxicity-doxorubicin-include-ischemic-heart-risk/ Tue, 24 May 2022 15:00:00 +0000 https://www.oncologynurseadvisor.com/?p=99237 A study compared patients with diffuse large B-cell lymphoma with a 1:10 cohort from the general population to determine the risk of cardiovascular events in patients receiving doxorubicin-containing regimens.]]> https://www.oncologynurseadvisor.com/home/cancer-types/breast-cancer/breast-cancer-regimen-safety-efficacy-men-similar-patients-treatment-risk/ Mon, 23 May 2022 15:00:00 +0000 https://www.oncologynurseadvisor.com/?p=99190 A subanalysis of the Compleement-1 trial investigated the safety and efficacy of the studied regimen for breast cancer in the 39 male participants of the study.]]> https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/myeloma-mitigation-strategies-successfully-reduce-incidence-adverse-effects/ Fri, 20 May 2022 15:00:00 +0000 https://www.oncologynurseadvisor.com/?p=99180 Researchers sought to identify predictors of movement and neurocognitive treatment-emergent adverse events in patients undergoing CAR-T therapy with ciltacabtagene autoleucel.]]>